197 related articles for article (PubMed ID: 22441015)
1. Hypoxia-induced autophagy: a new player in cancer immunotherapy?
Noman MZ; Janji B; Berchem G; Mami-Chouaib F; Chouaib S
Autophagy; 2012 Apr; 8(4):704-6. PubMed ID: 22441015
[TBL] [Abstract][Full Text] [Related]
2. Blocking hypoxia-induced autophagy in tumors restores cytotoxic T-cell activity and promotes regression.
Noman MZ; Janji B; Kaminska B; Van Moer K; Pierson S; Przanowski P; Buart S; Berchem G; Romero P; Mami-Chouaib F; Chouaib S
Cancer Res; 2011 Sep; 71(18):5976-86. PubMed ID: 21810913
[TBL] [Abstract][Full Text] [Related]
3. Effects of the tumor microenvironment on the efficacy of tumor immunotherapy.
Neeson P; Paterson Y
Immunol Invest; 2006; 35(3-4):359-94. PubMed ID: 16916758
[TBL] [Abstract][Full Text] [Related]
4. Hypoxia-inducible miR-210 regulates the susceptibility of tumor cells to lysis by cytotoxic T cells.
Noman MZ; Buart S; Romero P; Ketari S; Janji B; Mari B; Mami-Chouaib F; Chouaib S
Cancer Res; 2012 Sep; 72(18):4629-41. PubMed ID: 22962263
[TBL] [Abstract][Full Text] [Related]
5. Combined treatment targeting HIF-1α and Stat3 is a potent strategy for prostate cancer therapy.
Reddy KR; Guan Y; Qin G; Zhou Z; Jing N
Prostate; 2011 Dec; 71(16):1796-809. PubMed ID: 21480310
[TBL] [Abstract][Full Text] [Related]
6. Enhanced cancer immunotherapy using STAT3-depleted dendritic cells with high Th1-inducing ability and resistance to cancer cell-derived inhibitory factors.
Iwata-Kajihara T; Sumimoto H; Kawamura N; Ueda R; Takahashi T; Mizuguchi H; Miyagishi M; Takeda K; Kawakami Y
J Immunol; 2011 Jul; 187(1):27-36. PubMed ID: 21632716
[TBL] [Abstract][Full Text] [Related]
7. Immunogenic HLA-B*0702-restricted epitopes derived from human telomerase reverse transcriptase that elicit antitumor cytotoxic T-cell responses.
Adotévi O; Mollier K; Neuveut C; Cardinaud S; Boulanger E; Mignen B; Fridman WH; Zanetti M; Charneau P; Tartour E; Lemonnier F; Langlade-Demoyen P
Clin Cancer Res; 2006 May; 12(10):3158-67. PubMed ID: 16707616
[TBL] [Abstract][Full Text] [Related]
8. The HIF1alpha-inducible pro-cell death gene BNIP3 is a novel target of SIM2s repression through cross-talk on the hypoxia response element.
Farrall AL; Whitelaw ML
Oncogene; 2009 Oct; 28(41):3671-80. PubMed ID: 19668230
[TBL] [Abstract][Full Text] [Related]
9. Targeting Autophagy in the Tumor Microenvironment: New Challenges and Opportunities for Regulating Tumor Immunity.
Janji B; Berchem G; Chouaib S
Front Immunol; 2018; 9():887. PubMed ID: 29922284
[TBL] [Abstract][Full Text] [Related]
10. Hypoxia: a key player in antitumor immune response. A Review in the Theme: Cellular Responses to Hypoxia.
Noman MZ; Hasmim M; Messai Y; Terry S; Kieda C; Janji B; Chouaib S
Am J Physiol Cell Physiol; 2015 Nov; 309(9):C569-79. PubMed ID: 26310815
[TBL] [Abstract][Full Text] [Related]
11. Tumor resistance to specific lysis: a major hurdle for successful immunotherapy of cancer.
Chouaib S; Meslin F; Thiery J; Mami-Chouaib F
Clin Immunol; 2009 Jan; 130(1):34-40. PubMed ID: 19013109
[TBL] [Abstract][Full Text] [Related]
12. [Cytotoxic T lymphocytes: role in immunosurveillance and in immunotherapy].
Benchetrit F; Gazagne A; Adotevi O; Haicheur N; Godard B; Badoual C; Fridman WH; Tartour E
Bull Cancer; 2003; 90(8-9):677-85. PubMed ID: 14609756
[TBL] [Abstract][Full Text] [Related]
13. Autophagic degradation of GZMB/granzyme B: a new mechanism of hypoxic tumor cell escape from natural killer cell-mediated lysis.
Viry E; Baginska J; Berchem G; Noman MZ; Medves S; Chouaib S; Janji B
Autophagy; 2014 Jan; 10(1):173-5. PubMed ID: 24248158
[TBL] [Abstract][Full Text] [Related]
14. Gene transfer of antisense hypoxia inducible factor-1 alpha enhances the therapeutic efficacy of cancer immunotherapy.
Sun X; Kanwar JR; Leung E; Lehnert K; Wang D; Krissansen GW
Gene Ther; 2001 Apr; 8(8):638-45. PubMed ID: 11320410
[TBL] [Abstract][Full Text] [Related]
15. Hypoxia-adenosinergic immunosuppression: tumor protection by T regulatory cells and cancerous tissue hypoxia.
Sitkovsky MV; Kjaergaard J; Lukashev D; Ohta A
Clin Cancer Res; 2008 Oct; 14(19):5947-52. PubMed ID: 18829471
[TBL] [Abstract][Full Text] [Related]
16. Premortem autophagy determines the immunogenicity of chemotherapy-induced cancer cell death.
Martins I; Michaud M; Sukkurwala AQ; Adjemian S; Ma Y; Shen S; Kepp O; Menger L; Vacchelli E; Galluzzi L; Zitvogel L; Kroemer G
Autophagy; 2012 Mar; 8(3):413-5. PubMed ID: 22361584
[TBL] [Abstract][Full Text] [Related]
17. Eicosanoids and other lipid mediators and the tumor hypoxic microenvironment.
Krishnamoorthy S; Honn KV
Cancer Metastasis Rev; 2011 Dec; 30(3-4):613-8. PubMed ID: 22042480
[TBL] [Abstract][Full Text] [Related]
18. B-cell depletion using an anti-CD20 antibody augments antitumor immune responses and immunotherapy in nonhematopoetic murine tumor models.
Kim S; Fridlender ZG; Dunn R; Kehry MR; Kapoor V; Blouin A; Kaiser LR; Albelda SM
J Immunother; 2008 Jun; 31(5):446-57. PubMed ID: 18463540
[TBL] [Abstract][Full Text] [Related]
19. Hypoxia-induced autophagy: cell death or cell survival?
Mazure NM; Pouysségur J
Curr Opin Cell Biol; 2010 Apr; 22(2):177-80. PubMed ID: 20022734
[TBL] [Abstract][Full Text] [Related]
20. Hypoxia-dependent inhibition of tumor cell susceptibility to CTL-mediated lysis involves NANOG induction in target cells.
Hasmim M; Noman MZ; Lauriol J; Benlalam H; Mallavialle A; Rosselli F; Mami-Chouaib F; Alcaide-Loridan C; Chouaib S
J Immunol; 2011 Oct; 187(8):4031-9. PubMed ID: 21911602
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
